Broncus Holding Corp. subsidiary Broncus Hangzhou is acquiring Chinese medical device company Hangzhou Jingliang in the form of an equity transfer agreement for ¥5.4 million (US$758,000). The move will strengthen Broncus’ R&D capabilities in the flexible robotic space and will allow the company to offer pulmonology diagnostics and therapeutic solutions covering the complete product life cycle.
Johnson & Johnson completed the previously unheralded acquisition of privately held Laminar Inc. for $400 million upfront, with undisclosed contingent payments depending on achievement of clinical and regulatory milestones starting in 2024. The deal provides the med-tech giant a potentially game-changing entree into the lucrative left atrial appendage (LAA) market.
Smith+Nephew plc struck a deal to acquire Cartiheal Ltd. for $180 million at closing and $150 million in contingent payments, seven months after Bioventus Inc. backed out of its agreement to buy the developer of the Agili-C cartilage regeneration platform for $450 million.
Acutus Medical Inc. revealed plans after the Nasdaq closing bell on Nov. 8 to abandon the electrophysiology business as part of a massive restructuring that will leave the company entirely committed to manufacturing and distribution of Medtronic plc’s left-heart access products. The shift will put 65% of Acutus employees out of work and leaves the future of its cardiac ablation and mapping products up in the air.
The acquisition of Icad Inc.’s brachytherapy business by Elekta AB takes the company a step closer to achieving its goal of providing hope to the millions of people dealing with cancer, John Lapré, president of Elekta’s Brachy and Neuro Solutions unit, told BioWorld. Elekta paid approximately $5.5 million for Icad’s subsidiary Xoft. In addition, most of Xoft’s staff and its main facility in San José, Calif., was transferred to the company.
Med-tech saw some good news in October, with total financings value reaching $1.22 billion, an increase of 89.23% from the $645.75 million in September. However, the increase didn’t make up for the broader year-over-year decline in med-tech investments.
Just weeks after securing U.S. FDA approval for its flagship system to treat chronic limb-threatening ischemia (CLTI), Limflow SA kept the good news flowing to investors with the announcement of an agreement to be acquired by Inari Medical Inc. in a deal valued at up to $415 million. Inari will pay $250 million in cash at closing with up to $165 million in additional payments going to Limflow based on achievement of specified commercial and reimbursement milestones starting in 2025. The companies expect the deal to close by the end of the year.
There’s nothing scary for Ametek Inc. shareholders in the $1.9 billion acquisition of Paragon Medical Inc. announced on Oct. 31, 2023. The deal moves the industrial technology company solidly into the med-tech space as it picks up Paragon’s portfolio of products in orthopedics, minimally invasive surgery, robotic surgery and drug delivery, and adds an estimated $500 million per year in revenue and “very strong EPS accretion,” Ametek CEO David Zapico said in an investor call on Oct. 31.
United Therapeutics Corp. signed an agreement to acquire Miromatrix Medical Inc. for up to $140 million in cash, buying its way into additional organic growth. The deal would add Miromatrix’s comprehensive portfolio of bio-engineered organs to United’s existing organ production platform.
Hypnovr SAS recent takeover of Oncomfort SA will bring digital therapeutic solutions to a larger patient population suffering from pain and anxiety. Oncomfort has developed Digital Sedation, a non-pharmacological method of relieving patients’ pain and anxiety. This therapy, coupled with Hypnovr’s own virtual reality (VR) solution will help reduce medication use and improve the care pathway for patients undergoing medical procedures.
RSS
